A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3000 participants.

Also called NCT07900633

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 3,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07900633
  • EU CT 2026-525919-14-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Brazil, Canada, China, Czechia, France, Germany, Hungary, India, Italy, Japan, Mexico, Poland, Puerto Rico, Romania, South Korea, Spain, Türkiye, Ukraine (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07900633. Randomized; double masking; primary purpose treatment. Start 2026-12 (anticipated); primary completion 2029-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
Acronym
ENLIGHTEN-10
Condition
Obesity
Condition
Overweight
Condition
Cardiovascular Diseases
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Eloralintide
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct07900633
Content hash
9051759123aa390c501a311493f4698e779964c1364967ce0fc99b1e8531263b